These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15802227)

  • 1. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli.
    Hijnen M; van Gageldonk PG; Berbers GA; van Woerkom T; Mooi FR
    Protein Expr Purif; 2005 May; 41(1):106-12. PubMed ID: 15802227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.
    Hijnen M; Mooi FR; van Gageldonk PG; Hoogerhout P; King AJ; Berbers GA
    Infect Immun; 2004 Jul; 72(7):3716-23. PubMed ID: 15213111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity.
    King AJ; Berbers G; van Oirschot HF; Hoogerhout P; Knipping K; Mooi FR
    Microbiology (Reading); 2001 Nov; 147(Pt 11):2885-95. PubMed ID: 11700340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland.
    Mooi FR; He Q; van Oirschot H; Mertsola J
    Infect Immun; 1999 Jun; 67(6):3133-4. PubMed ID: 10338531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.
    Hijnen M; He Q; Schepp R; Van Gageldonk P; Mertsola J; Mooi FR; Berbers GA
    Scand J Infect Dis; 2008; 40(2):94-104. PubMed ID: 17926203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of recombinant and native pertactin of Bordetella pertussis.
    Xu Y; Zhang S; Bolgiano B; Tan Y; Asokanathan C; Zhang H; Xing D; Wang J
    Vaccine; 2011 Feb; 29(10):1974-80. PubMed ID: 21216309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution.
    Mooi FR; van Oirschot H; Heuvelman K; van der Heide HG; Gaastra W; Willems RJ
    Infect Immun; 1998 Feb; 66(2):670-5. PubMed ID: 9453625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of linear B epitopes of pertactin of Bordetella pertussis induced by immunization with whole and acellular vaccine.
    da Silva FR; Napoleão-Pego P; De-Simone SG
    Vaccine; 2014 Oct; 32(47):6251-8. PubMed ID: 25252193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
    Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
    Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
    Hegerle N; Dore G; Guiso N
    Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.
    Fry NK; Neal S; Harrison TG; Miller E; Matthews R; George RC
    Infect Immun; 2001 Sep; 69(9):5520-8. PubMed ID: 11500425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?
    He Q; Mäkinen J; Berbers G; Mooi FR; Viljanen MK; Arvilommi H; Mertsola J
    J Infect Dis; 2003 Apr; 187(8):1200-5. PubMed ID: 12695998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
    Byrne S; Slack AT
    BMC Infect Dis; 2006 Mar; 6():53. PubMed ID: 16542440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition.
    Hijnen M; de Voer R; Mooi FR; Schepp R; Moret EE; van Gageldonk P; Smits G; Berbers GA
    Vaccine; 2007 Aug; 25(31):5902-14. PubMed ID: 17597264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.
    Xu Y; Wang Y; Tan Y; Zhang H; Wu L; Wang L; Hou Q; Zhang S
    BMC Microbiol; 2009 Dec; 9():274. PubMed ID: 20040101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare Detection of Bordetella pertussis Pertactin-Deficient Strains in Argentina.
    Carriquiriborde F; Regidor V; Aispuro PM; Magali G; Bartel E; Bottero D; Hozbor D
    Emerg Infect Dis; 2019 Nov; 25(11):2048-2054. PubMed ID: 31625838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
    Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
    Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells.
    Everest P; Li J; Douce G; Charles I; De Azavedo J; Chatfield S; Dougan G; Roberts M
    Microbiology (Reading); 1996 Nov; 142 ( Pt 11)():3261-8. PubMed ID: 8969522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bordetella parapertussis isolates not expressing pertactin circulating in France.
    Bouchez V; Brun D; Dore G; Njamkepo E; Guiso N
    Clin Microbiol Infect; 2011 May; 17(5):675-82. PubMed ID: 20636430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
    Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA
    Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.